source
- STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and moreSanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issuesSTAT · 2h ago↗ source
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drugScholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…Fierce Biotech · 5h ago↗ source
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.